Goldman Sachs
BTAI icon

Goldman Sachs’s BioXcel Therapeutics BTAI Stock Holding History

Goldman Sachs’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,794
Closed -$50.3K – 6102
2025
Q1 		$50.3K Buy
+24,794
New +$92.6K ﹤0.01% 5878
2024
Q3 		– Sell
-6,185
Closed -$127K – 5827
2024
Q2 		$127K Buy
6,185
+4,762
+335% +$159K ﹤0.01% 5371
2024
Q1 		$64.2K Buy
1,423
+223
+19% +$10.6K ﹤0.01% 5297
2023
Q4 		$56.6K Sell
1,200
-7,105
-86% -$395K ﹤0.01% 5359
2023
Q3 		$336K Sell
8,305
-698
-8% -$70.6K ﹤0.01% 4841
2023
Q2 		$959K Sell
9,003
-1,225
-12% -$408K ﹤0.01% 4365
2023
Q1 		$3.05M Buy
10,228
+6,889
+206% +$2.94M ﹤0.01% 3513
2022
Q4 		$1.15M Sell
3,339
-2,505
-43% -$606K ﹤0.01% 4337
2022
Q3 		$1.11M Buy
5,844
+1,302
+29% +$302K ﹤0.01% 4430
2022
Q2 		$959K Buy
4,542
+245
+6% +$51.5K ﹤0.01% 4642
2022
Q1 		$1.44M Buy
4,297
+1,189
+38% +$345K ﹤0.01% 4537
2021
Q4 		$1.01M Buy
3,108
+860
+38% +$369K ﹤0.01% 4827
2021
Q3 		$1.09M Sell
2,248
-8,851
-80% -$3.89M ﹤0.01% 4676
2021
Q2 		$5.16M Buy
11,099
+3,195
+40% +$1.74M ﹤0.01% 3308
2021
Q1 		$5.46M Sell
7,904
-6,136
-44% -$4.94M ﹤0.01% 3060
2020
Q4 		$10.4M Buy
14,040
+6,064
+76% +$4.72M ﹤0.01% 2432
2020
Q3 		$5.53M Buy
7,976
+1,727
+28% +$1.3M ﹤0.01% 2815
2020
Q2 		$5.3M Buy
6,249
+3,130
+100% +$2.04M ﹤0.01% 2765
2020
Q1 		$1.12M Buy
+3,119
New +$1.12M ﹤0.01% 3675
2018
Q3 		– Sell
-664
Closed -$98K – 5565
2018
Q2 		$98K Sell
664
-1,079
-62% -$165K ﹤0.01% 5220
2018
Q1 		$285K Buy
+1,743
New +$291K ﹤0.01% 4809

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Goldman Sachs's BTAI Position: Q2 2025 in Review

Goldman Sachs sold out of BioXcel Therapeutics (BTAI) in Q2 2025, closing a stake of 24,794 shares — an estimated $50.3K sold.

Goldman Sachs first reported a position in BTAI in Q1 2018 and held it in 21 quarters. The position peaked at $10.4M in Q4 2020. 35 funds tracked by Wall St. Rank hold BTAI as of Q2 2025.

  • Goldman Sachs reported no remaining BioXcel Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 24,794 BioXcel Therapeutics shares in Q2 2025, an estimated $50.3K.
  • Goldman Sachs first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 21 quarters.
  • Goldman Sachs's BioXcel Therapeutics position peaked at $10.4M in Q4 2020.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.